SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLES:

Table supplementary 1. Adverse events and treatment-related adverse events (ITT analysis set).

Adverse Event (CTC)	ADVERSE EVENTS						TREATMENT-RELATED ADVERSE EVENTS					
	All grade			Grade ≥3			All grade			Grade ≥3		
	40mg/m^2 (n=17)	30mg/m^2 (n=14)	Total (n=31)	40mg/m^2 (n=17)	30mg/m^2 (n=14)	Total (n=31)	40mg/m^2 (n=17)	30mg/m^2 (n=14)	Total (n=31)	40mg/m^2 (n=17)	30mg/m^2 (n=14)	Total (n=31)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Nausea	10 (59%)	12 (86%)	22 (71%)	1 (6%)	1 (7%)	2 (7%)	7 (41%)	11 (79%)	18 (58%)	-	1 (7%)	1 (3%)
Fatigue	11 (65%)	10 (71%)	21 (68%)	2 (12%)	1 (7%)	3 (10%)	8 (47%)	9 (64%)	17 (55%)	2 (12%)	1 (7%)	3 (10%)
Vomiting	9 (53%)	8 (57%)	17 (55%)	1 (6%)	1 (7%)	2 (7%)	7 (41%)	7 (50%)	14 (45%)	1 (6%)	1 (7%)	2 (7%)
Anemia	12 (71%)	6 (43%)	18 (58%)	4 (24%)	3 (21%)	7 (23%)	11 (65%)	6 (43%)	17 (55%)	4 (24%)	3 (21%)	7 (23%)
Neutrophil count decreased	8 (47%)	8 (57%)	16 (52%)	7 (41%)	5 (36%)	12 (39%)	8 (47%)	7 (50%)	15 (48%)	10 (59%)*	5 (36%)	15 (48%)*
Diarrhea	8 (47%)	3 (21%)	11 (36%)	1 (6%)	-	1 (3%)	6 (35%)	3 (21%)	9 (29%)	1 (6%)	-	1 (3%)
Constipation	9 (53%)	3 (21%)	12 (39%)	-	-	-	-	-	-	-	-	-
Mucositis oral	8 (47%)	2 (14%)	10	1 (6%)	-	1 (3%)	8 (47%)	1 (7%)	9 (29%)	1 (6%)	-	1 (3%)

			(32%)									
Platelet count decreased	4 (24%)	3 (21%)	7 (23%)	2 (12%)	1 (7%)	3 (10%)	4 (24%)	2 (14%)	6 (19%)	2 (12%)	1 (7%)	3 (10%)
Anorexia	4 (24%)	4 (29%)	8 (26%)	-	-	-	3 (18%)	3 (21%)	6 (19%)	-	-	-
White blood cell decreased	6 (35%)	-	6 (19%)	4 (24%)	-	4 (13%)	5 (29%)	-	5 (16%)	3 (18%)	-	3 (10%)
Intestinal obstruction	5 (29%)	2 (14%)	7 (23%)	4 (24%)	2 (14%)	6 (19%)	-	-	-	-	-	-
Abdominal pain	4 (24%)	2 (14%)	6 (19%)	-	-	-	-	-	-	-	-	-
Headache	1 (6%)	3 (21%)	4 (13%)	-	-	-	-	-	-	-	-	-
Renal and urinary disorders: Pyelonephritis	-	1 (7%)	1 (3%)	-	1 (7%)	1 (3%)	-	1 (7%)	1 (3%)	-	1 (7%)	1 (3%)
In this table, toxicities are grouped using the maximum grade reported for each patient												
* 3 febrile neutropenias included												

Table Supplementary 2. Related SAEs vs PLD dose (ITT analysis set). Total number of related SAE, 1 patient had an event in the PLD30 group and 3 patients in the PDL40 group had one or more events.

Related SAEs vs PLD dose (ITT)				
Related Serious Adverse Event (CTCAE)	**Grade**	**Dose of PLD**		
		40mg/m2	**30mg/m2**	**Total**
		N (%)	**N (%)**	**N (%)**
Febrile neutropenia	**G4**	1 (6%)	0 (0%)	1 (3%)
Neutrophil count decrease	**G3**	1 (6%)	0 (0%)	1 (3%)
Anemia	**G3**	1 (6%)	0 (0%)	1 (3%)
Mucositis oral	**G4**	1 (6%)	0 (0%)	1 (3%)
	G3	1 (6%)	0 (0%)	1 (3%)
Renal and urinary disorders - Other	**G3**	0 (0%)	1 (7%)	1 (3%)

SUPPLEMENTARY FIGURES:

Figure Supplementary 1. A) Progression-free survival in the ITT analysis set in the stratified analysis according to the BRCA mutational status: BRCA-wt (Dark blue) and BRCA-mut (Light blue). B) Overall survival in the ITT analysis set according to BRCA status. Patients with unknown BRCA status were not considered for both stratified analysis.



Figure Supplementary 2. The QLQ-C30 score in the intent-to-treat (ITT) analysis set. The score ranges from 0 to 100, with higher scores indicating better functioning/fewer symptoms. The score integrates the result from 13 scales comprising functional and symptomatology assessments.